| Ssm Health Medical Group - Family Medicine | |
|
100 Highway 28 E Belle MO 65013-3405 | |
| (573) 859-3775 | |
| (573) 859-3997 |
| Full Name | Ssm Health Medical Group - Family Medicine |
|---|---|
| Speciality | Clinic/Center |
| Location | 100 Highway 28 E, Belle, Missouri |
| Authorized Official Name and Position | James T Stratton (CFO) |
| Authorized Official Contact | 5736813129 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Ssm Health Medical Group - Family Medicine Po Box 1027 Jefferson City MO 65102-1027 Ph: (573) 681-3767 | Ssm Health Medical Group - Family Medicine 100 Highway 28 E Belle MO 65013-3405 Ph: (573) 859-3775 |
| NPI Number | 1659327393 |
|---|---|
| Provider Enumeration Date | 05/25/2006 |
| Last Update Date | 06/20/2022 |
| Medicare PECOS PAC ID | 8921917352 |
|---|---|
| Medicare Enrollment ID | O20050322000373 |
News Archive
Severe acute pancreatitis (SAP) requires an adequate nutritional support. Enteral nutrition (EN) should be preferred to total parenteral nutrition in patients with SAP, as it is associated with reduced mortality and complications. However, in clinical practice EN is employed far less frequently than it should. The main obstacle to EN diffusion is that it is considered complicated, as to ensure full pancreatic rest, nutrition tubes should be placed in the jejunum, requiring often troublesome procedures. In the past few years, it has been proposed that EN through nasogastric (NG) tubes may be a simple, safe and equally valid alternative to nasojejunal tubes.
A pioneering world first robotics system operation is to be conducted at Glenfield Hospital Leicester thanks to expertise at the University of Leicester and University Hospitals of Leicester.
Amgen today announced the initiation of the ARROW trial, a global Phase 3 study evaluating the benefit of Kyprolis® (carfilzomib) for Injection administered once-weekly with dexamethasone versus the current U.S. Food and Drug Administration (FDA) approved twice-weekly administration schedule in patients with relapsed and refractory multiple myeloma who have received prior treatment with bortezomib and an immunomodulatory agent (IMiD).
Customized, biomedically applicable materials based on tropoelastin are being developed in a joint project by Skinomics GmbH from Halle, Martin Luther University Halle-Wittenberg and the Fraunhofer Institute for Microstructure of Materials and Systems IMWS.
› Verified 3 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1659327393 | NPI | - | NPPES |
| 503825606 | Medicaid | MO |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 261Q00000X | Clinic/center | (* (Not Available)) | Secondary |
| 261QR1300X | Clinic/center - Rural Health | (* (Not Available)) | Primary |
| Provider Name | Mark A Rosales |
|---|---|
| Provider Type | Practitioner - Hospice/palliative Care |
| Provider Identifiers | NPI Number: 1962446070 PECOS PAC ID: 5294741278 Enrollment ID: I20060228000597 |
News Archive
Severe acute pancreatitis (SAP) requires an adequate nutritional support. Enteral nutrition (EN) should be preferred to total parenteral nutrition in patients with SAP, as it is associated with reduced mortality and complications. However, in clinical practice EN is employed far less frequently than it should. The main obstacle to EN diffusion is that it is considered complicated, as to ensure full pancreatic rest, nutrition tubes should be placed in the jejunum, requiring often troublesome procedures. In the past few years, it has been proposed that EN through nasogastric (NG) tubes may be a simple, safe and equally valid alternative to nasojejunal tubes.
A pioneering world first robotics system operation is to be conducted at Glenfield Hospital Leicester thanks to expertise at the University of Leicester and University Hospitals of Leicester.
Amgen today announced the initiation of the ARROW trial, a global Phase 3 study evaluating the benefit of Kyprolis® (carfilzomib) for Injection administered once-weekly with dexamethasone versus the current U.S. Food and Drug Administration (FDA) approved twice-weekly administration schedule in patients with relapsed and refractory multiple myeloma who have received prior treatment with bortezomib and an immunomodulatory agent (IMiD).
Customized, biomedically applicable materials based on tropoelastin are being developed in a joint project by Skinomics GmbH from Halle, Martin Luther University Halle-Wittenberg and the Fraunhofer Institute for Microstructure of Materials and Systems IMWS.
› Verified 3 days ago
| Provider Name | Shannon Wright |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1619033404 PECOS PAC ID: 2668579871 Enrollment ID: I20070523000456 |
News Archive
Severe acute pancreatitis (SAP) requires an adequate nutritional support. Enteral nutrition (EN) should be preferred to total parenteral nutrition in patients with SAP, as it is associated with reduced mortality and complications. However, in clinical practice EN is employed far less frequently than it should. The main obstacle to EN diffusion is that it is considered complicated, as to ensure full pancreatic rest, nutrition tubes should be placed in the jejunum, requiring often troublesome procedures. In the past few years, it has been proposed that EN through nasogastric (NG) tubes may be a simple, safe and equally valid alternative to nasojejunal tubes.
A pioneering world first robotics system operation is to be conducted at Glenfield Hospital Leicester thanks to expertise at the University of Leicester and University Hospitals of Leicester.
Amgen today announced the initiation of the ARROW trial, a global Phase 3 study evaluating the benefit of Kyprolis® (carfilzomib) for Injection administered once-weekly with dexamethasone versus the current U.S. Food and Drug Administration (FDA) approved twice-weekly administration schedule in patients with relapsed and refractory multiple myeloma who have received prior treatment with bortezomib and an immunomodulatory agent (IMiD).
Customized, biomedically applicable materials based on tropoelastin are being developed in a joint project by Skinomics GmbH from Halle, Martin Luther University Halle-Wittenberg and the Fraunhofer Institute for Microstructure of Materials and Systems IMWS.
› Verified 3 days ago
| Provider Name | Tricia D Temmen |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1285974774 PECOS PAC ID: 2769627926 Enrollment ID: I20130319000066 |
News Archive
Severe acute pancreatitis (SAP) requires an adequate nutritional support. Enteral nutrition (EN) should be preferred to total parenteral nutrition in patients with SAP, as it is associated with reduced mortality and complications. However, in clinical practice EN is employed far less frequently than it should. The main obstacle to EN diffusion is that it is considered complicated, as to ensure full pancreatic rest, nutrition tubes should be placed in the jejunum, requiring often troublesome procedures. In the past few years, it has been proposed that EN through nasogastric (NG) tubes may be a simple, safe and equally valid alternative to nasojejunal tubes.
A pioneering world first robotics system operation is to be conducted at Glenfield Hospital Leicester thanks to expertise at the University of Leicester and University Hospitals of Leicester.
Amgen today announced the initiation of the ARROW trial, a global Phase 3 study evaluating the benefit of Kyprolis® (carfilzomib) for Injection administered once-weekly with dexamethasone versus the current U.S. Food and Drug Administration (FDA) approved twice-weekly administration schedule in patients with relapsed and refractory multiple myeloma who have received prior treatment with bortezomib and an immunomodulatory agent (IMiD).
Customized, biomedically applicable materials based on tropoelastin are being developed in a joint project by Skinomics GmbH from Halle, Martin Luther University Halle-Wittenberg and the Fraunhofer Institute for Microstructure of Materials and Systems IMWS.
› Verified 3 days ago
| Provider Name | Joanna L Younker |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1114278124 PECOS PAC ID: 1254648025 Enrollment ID: I20170928000503 |
News Archive
Severe acute pancreatitis (SAP) requires an adequate nutritional support. Enteral nutrition (EN) should be preferred to total parenteral nutrition in patients with SAP, as it is associated with reduced mortality and complications. However, in clinical practice EN is employed far less frequently than it should. The main obstacle to EN diffusion is that it is considered complicated, as to ensure full pancreatic rest, nutrition tubes should be placed in the jejunum, requiring often troublesome procedures. In the past few years, it has been proposed that EN through nasogastric (NG) tubes may be a simple, safe and equally valid alternative to nasojejunal tubes.
A pioneering world first robotics system operation is to be conducted at Glenfield Hospital Leicester thanks to expertise at the University of Leicester and University Hospitals of Leicester.
Amgen today announced the initiation of the ARROW trial, a global Phase 3 study evaluating the benefit of Kyprolis® (carfilzomib) for Injection administered once-weekly with dexamethasone versus the current U.S. Food and Drug Administration (FDA) approved twice-weekly administration schedule in patients with relapsed and refractory multiple myeloma who have received prior treatment with bortezomib and an immunomodulatory agent (IMiD).
Customized, biomedically applicable materials based on tropoelastin are being developed in a joint project by Skinomics GmbH from Halle, Martin Luther University Halle-Wittenberg and the Fraunhofer Institute for Microstructure of Materials and Systems IMWS.
› Verified 3 days ago
News Archive
Severe acute pancreatitis (SAP) requires an adequate nutritional support. Enteral nutrition (EN) should be preferred to total parenteral nutrition in patients with SAP, as it is associated with reduced mortality and complications. However, in clinical practice EN is employed far less frequently than it should. The main obstacle to EN diffusion is that it is considered complicated, as to ensure full pancreatic rest, nutrition tubes should be placed in the jejunum, requiring often troublesome procedures. In the past few years, it has been proposed that EN through nasogastric (NG) tubes may be a simple, safe and equally valid alternative to nasojejunal tubes.
A pioneering world first robotics system operation is to be conducted at Glenfield Hospital Leicester thanks to expertise at the University of Leicester and University Hospitals of Leicester.
Amgen today announced the initiation of the ARROW trial, a global Phase 3 study evaluating the benefit of Kyprolis® (carfilzomib) for Injection administered once-weekly with dexamethasone versus the current U.S. Food and Drug Administration (FDA) approved twice-weekly administration schedule in patients with relapsed and refractory multiple myeloma who have received prior treatment with bortezomib and an immunomodulatory agent (IMiD).
Customized, biomedically applicable materials based on tropoelastin are being developed in a joint project by Skinomics GmbH from Halle, Martin Luther University Halle-Wittenberg and the Fraunhofer Institute for Microstructure of Materials and Systems IMWS.
› Verified 3 days ago